ImmunityBio (NASDAQ:IBRX) Given “Buy” Rating at D. Boral Capital

ImmunityBio (NASDAQ:IBRX)‘s stock had its “buy” rating reaffirmed by analysts at D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They presently have a $30.00 price objective on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating on shares of ImmunityBio in a report on Monday, May 5th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, ImmunityBio presently has a consensus rating of “Buy” and an average target price of $12.19.

ImmunityBio Trading Up 6.4%

Shares of NASDAQ:IBRX opened at $2.51 on Monday. The stock has a 50 day moving average of $2.66 and a 200 day moving average of $3.35. The company has a market cap of $2.22 billion, a PE ratio of -2.73 and a beta of 0.33. ImmunityBio has a 12-month low of $1.83 and a 12-month high of $9.16.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.03). The business had revenue of $16.52 million during the quarter, compared to analyst estimates of $17.50 million. Equities research analysts predict that ImmunityBio will post -0.92 earnings per share for the current fiscal year.

Institutional Trading of ImmunityBio

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in ImmunityBio by 17.4% during the 1st quarter. Vanguard Group Inc. now owns 20,344,554 shares of the company’s stock valued at $61,237,000 after buying an additional 3,016,325 shares during the period. Woodline Partners LP raised its holdings in ImmunityBio by 682.7% during the 4th quarter. Woodline Partners LP now owns 3,442,440 shares of the company’s stock valued at $8,813,000 after buying an additional 3,002,622 shares during the period. Tang Capital Management LLC purchased a new stake in ImmunityBio during the 4th quarter valued at $7,204,000. Citigroup Inc. raised its holdings in ImmunityBio by 605.9% during the 1st quarter. Citigroup Inc. now owns 2,714,662 shares of the company’s stock valued at $8,171,000 after buying an additional 2,330,086 shares during the period. Finally, Northern Trust Corp raised its holdings in ImmunityBio by 7.9% during the 4th quarter. Northern Trust Corp now owns 1,323,424 shares of the company’s stock valued at $3,388,000 after buying an additional 97,348 shares during the period. Hedge funds and other institutional investors own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.